EDUCATION

Breast Cancer Molecular Testing: Catching Up to Increased Complexity

 

LIVE WEBINAR: Predictive Tests for Therapeutic Options in Breast Cancer: Indications, Utility, and Interpretation

September 21, 2023 | 4:00PM Eastern

Register Now!

This four-part webinar series will address molecular testing in breast cancer, covering areas such as multi-gene assays, therapeutic predictive testing, somatic next-generation sequencing, and germline testing. The series will provide pathologists with a comprehensive understanding of breast cancer molecular testing, from test selection to interpretation which will ultimately lead to optimal patient care in a rapidly evolving field.

 

At the end of the series, participants will be able to:

  • Describe the purpose of specific multi-gene assays in breast cancer
  • Recognize the correct conditions for applying multi-gene assay testing,
  • Employ best practices to identify correct specimen type and tumor area for specific molecular diagnostic tests
  • List available predictive tests for therapeutic options in breast cancer,
  • Discuss the utility and pitfalls of comprehensive next-generation sequencing assays for somatic tumor testing in breast cancer
  • Apply best practices in interpretation of germline variants applicable to hereditary breast cancer
  • Identify barriers to access to molecular services for patients with breast cancer and describe potential solutions

 

TARGET AUDIENCE

Pathologists (molecular and non-molecular), clinical laboratory directors, trainees and fellows, and other laboratory professionals (managers and technologists). Also, oncologists (including medical and clinical oncologists), breast surgeons, oncology nurses, and other members of the oncology care team.

 

SCHEDULE

Webinar #1: An Overview of Multi-Gene Expression Assays in Breast Cancer
Speakers:
Mara Rendi, MD 
Date: August 23, 2023 
Time: 11:00 am ET
Instant access here

Webinar #2: Predictive Tests for Therapeutic Options in Breast Cancer: Indications, Utility, and Interpretation
Speakers:
 Kimberly Allison, MD
Date: September 21, 2023 
Time: 4:00 pm ET
Register here

Webinar #3: Application of Next-Generation Sequencing in Somatic Tumor Testing in Breast Cancer
Speakers:
TBD
Date: February 2024

Webinar #4: Challenges in Breast Cancer Susceptibility Genetic Testing
Speakers:
TBD
Date: March/April 2024
 

CONTENT COMMITTEE

This webinar series is planned and coordinated by the Breast Cancer Webinar Series Content Committee:

Lulu Sun, MD, PhD (Chair)
Washington University in St. Louis

Melissa Krystel-Whittemore, MD
NYU Langone

Gregory Bean, MD, PhD
Stanford University School of Medicine

 

Chieh-Yu Lin, MD, PhD
Washington University in St. Louis
 

Eli Williams, PhD
(T&E Committee Liaison)
University of Virginia


And supported by the AMP Training & Education Committee

 

CONTINUING EDUCATION CREDIT INFORMATION

Accreditation Statements
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™per webinar. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit per webinar. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
 
This activity is supported by an educational grant from Lilly.

Corporate Partners